Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care

AIDS

Volumn 27, Issue 18, 2013, Pages 2873-2881

  Soeters, Heidi M ^a   Napravnik, Sonia ^a,b,c   Zakharova, Oksana M ^b,c   Eron, Joseph J ^b,c   Hurt, Christopher B ^b  

^a Department of Epidemiology ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antiretroviral therapy; Clinical cohort; HIV; Sexual behaviour; Transmitted drug resistance

Indexed keywords

VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONDOM USE; CROSS-SECTIONAL STUDY; DRUG RESISTANCE; FEMALE; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEGRO; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; TRANSMITTED DRUG RESISTANCE; UNPROTECTED SEX; AGED; DISEASE TRANSMISSION; DRUG EFFECTS; GENOTYPING TECHNIQUE; HIGH RISK BEHAVIOR; HUMAN IMMUNODEFICIENCY VIRUS; INTERVIEW; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MISSENSE MUTATION; TRANSMISSION; VIREMIA; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPING TECHNIQUES; HIV; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; RETROSPECTIVE STUDIES; RISK-TAKING; VIREMIA; YOUNG ADULT;

EID: 84888290115     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000433240.78739.30     Document Type: Article

References (46)

1. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV Incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502.
2. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24:1203-1212.
3. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53:696-699.
4. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:65-72.
5. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008; 197 (Suppl 3):S272-S278.
6. Tam LW, Chui CK, Brumme CJ, Bangsberg DR, Montaner JS, Hogg RS, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr 2008; 49:266-271.
7. Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, et al. Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS 2008; 22:2509-2515.
8. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339:307-311.
9. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282: 1135-1141.
10. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-23.
11. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
12. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
13. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180.
14. Ross L, LimML, LiaoQ,Wine B,RodriguezAE,WeinbergW,et al. Prevalence of antiretroviral drug resistance and resistanceassociated mutations in antiretroviral therapy-naive HIVinfected individuals from 40 United States cities. HIV Clin Trials 2007; 8:1-8.
15. Hurt CB, McCoy SI, Kuruc J, Nelson JA, Kerkau M, Fiscus S, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009; 14:673-678.
16. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. Time trends in primary resistance to HIV drugs in the United Kingdom:multicentre observational study.BMJ2005; 331:1368.
17. Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jorgensen LB, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005; 40:505-511.
18. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005; 192:958-966.
19. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009; 200:1503-1508.
20. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, et al. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003; 187:683-686.
21. Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, et al. Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. J Infect Dis 2009; 199:427-431.
22. Marks G, Burris S, Peterman TA. Reducing sexual transmission of HIV from those who know they are infected: the need for personal and collective responsibility. AIDS 1999; 13:297-306.
23. Kline A, VanLandingham M. HIV-infected women and sexual risk reduction: the relevance of existing models of behavior change. AIDS Educ Prev 1994; 6:390-402.
24. Wenger NS, Kusseling FS, Beck K, Shapiro MF. Sexual behavior of individuals infected with the human immunodeficiency virus. The need for intervention. Arch Intern Med 1994; 154: 1849-1854.
25. van Kesteren NM, Hospers HJ, Kok G. Sexual risk behavior among HIV-positive men who have sex with men: A literature review. Patient Educ Couns 2007; 65:5-20.
26. van der Straten A, Gomez CA, Saul J, Quan J, Padian N. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of postexposure prevention and viral suppressive therapy. AIDS 2000; 14:F47-F54.
27. Fox J, White PJ, Macdonald N, Weber J, McClure M, Fidler S, et al. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: A cohort of high-risk men who have sex with men. HIV Med 2009; 10:432-438.
28. de Wit JB, van Griensven GJ. Time from safer to unsafe sexual behaviour among homosexual men. AIDS 1994; 8:123-126.
29. Adib SM, Joseph JG, Ostrow DG, Tal M, Schwartz SA. Relapse in sexual behavior among homosexual men: A 2-year follow-up from the Chicago MACS/CCS. AIDS 1991; 5:757-760.
30. Flaks RC, Burman WJ, Gourley PJ, Rietmeijer CA, Cohn DL. HIV transmission risk behavior and its relation to antiretroviral treatment adherence. Sex Transm Dis 2003; 30:399-404.
31. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect 2003; 79:59-61.
32. Kozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D, Fisher W, et al. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS 2004; 18:2185-2189.
33. Chin-Hong PV, Deeks SG, Liegler T, Hagos E, Krone MR, Grant RM, et al. High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection. J Acquir Immune Defic Syndr 2005; 40:463-471.
34. Remien RH, Exner TM, Morin SF, Ehrhardt AA, Johnson MO, Correale J, et al. Medication adherence and sexual risk behavior among HIV-infected adults: Implications for transmission of resistant virus. AIDS Behav 2007; 11:663-675.
35. Howe CJ, Cole SR, Napravnik S, Eron JJ. Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses 2010; 26:875-881.
36. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255-266.
37. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002; 97:1183-1194.
38. Babor TF, Higgins-Biddle JC, Saunders JB, Monteriro MG. AUDIT: The Alcohol Use Disorders Identification Test: guidelines for use in primary care. 2nd ed. Geneva, Switzerland: WHO; 2001.
39. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
40. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223.
41. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Washington, DC: US Department of Health and Human Services; 2012. pp. 1-239.
42. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
43. Kidder DP, Wolitski RJ, Campsmith ML, Nakamura GV. Health status, healthcare use, medication use, and medication adherence among homeless and housed people living with HIV/AIDS. Am J Public Health 2007; 97:2238-2245.
44. Wilson TE, Barrón Y, Cohen M, Richardson J, Greenblatt R, Sacks HS, et al. Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis 2002; 34:529-534.
45. Sethi AK, Celentano DD, Gange SJ, Gallant JE, Vlahov D, Farzadegan H. High-risk behavior and potential transmission of drug-resistant HIV among injection drug users. J Acquir Immune Defic Syndr 2004; 35:503-510.
46. CDC. Incorporating HIV prevention into the medical care of persons living with HIV: recommendations of CDC, the Heatlh Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52:1-24.